Unique ID issued by UMIN | UMIN000003871 |
---|---|
Receipt number | R000004659 |
Scientific Title | Prospective, randomized, double-blind, controlled study for the incidence of small bowel mucosal injury caused by selective COX-2 inhibitor in healthy volunteers |
Date of disclosure of the study information | 2010/07/05 |
Last modified on | 2011/07/13 22:29:32 |
Prospective, randomized, double-blind, controlled study for the incidence of small bowel mucosal injury caused by selective COX-2 inhibitor in healthy volunteers
Clinical trial for the incidence of small bowel mucosal injury by selective COX-2 inhibitor
Prospective, randomized, double-blind, controlled study for the incidence of small bowel mucosal injury caused by selective COX-2 inhibitor in healthy volunteers
Clinical trial for the incidence of small bowel mucosal injury by selective COX-2 inhibitor
Japan |
Small bowel mucosal injury
Gastroenterology |
Others
NO
The aim of the study is to ascertain the superiority of celecoxib, a selective COX-2 inhibitor, for the small bowel mucosal injury in comparison to meloxicam, a NSAID with preferential COX-2 inhibition.
Safety,Efficacy
The number and incidence of small bowel pathologies (ulcer, hemorrhage and mucosal break) under capsule endoscopy after 2 weeks medication.
Abdominal symptoms and laboratory data including anemia
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Active
Central registration
2
Treatment
Medicine |
Subjects in celecoxib group are administered celecoxib 200mg twice per day for two weeks.
Subjects in meloxicam group are administered meloxicam 10mg once per day for two weeks.
20 | years-old | <= |
75 | years-old | > |
Male and Female
Healthy volunteers obtained written informed consent
1) Subjects with a history of peptic ulcers
2) Subjects treated by corticosteroid (>10mg of prednisolone)
3) Subjects treated continuously with NSAIDs
4) Subjects treated with aspirin
5) Subjects with a history of aspirin-induced asthma
6) Subjects allergic to sulufonamids
7) Subjects treated with anti-ulcer drugs (misoprostol, rebamipide, teprenone, etc)
8) Subjects with stenosis of gastrointestinal tract or severe adhesion
9) Subjects with malignancy, psychosis, severe hepatic, renal dysfunction, heart disease, or hematologic disease
10) Pregnant and nursing women
11) Subjects with other disorders who are judged as inappropriate for the participation of the study
40
1st name | |
Middle name | |
Last name | Takayuki Matsumoto |
Graduate School of Medical Sciences, Kyushu University
Department of Medicine and Clinical Science
Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan
092-642-5261
1st name | |
Middle name | |
Last name | Motohiro Esaki, Yuji Maehata |
Graduate School of Medical Sciences, Kyushu University
Department of Medicine and Clinical Science
Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan
092-642-5261
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
Other
Japan
Fukuoka Sanno Hospital
YES
FS-2-0903-049
International university of health and welfare graduate school
2010 | Year | 07 | Month | 05 | Day |
Unpublished
Completed
2009 | Year | 07 | Month | 28 | Day |
2010 | Year | 04 | Month | 01 | Day |
2010 | Year | 08 | Month | 01 | Day |
2010 | Year | 08 | Month | 01 | Day |
2010 | Year | 09 | Month | 01 | Day |
2011 | Year | 03 | Month | 01 | Day |
2010 | Year | 07 | Month | 05 | Day |
2011 | Year | 07 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004659